Bris­tol My­ers wins a big bet as their PhI­II au­toim­mune drug beat out block­buster Ote­zla — and that could cost Am­gen dear­ly

Bris­tol My­ers Squibb $BMY bet big on a Phase III pso­ri­a­sis pro­gram for its TYK2 con­tender deu­cravac­i­tinib (BMS-986165). And to­day they’re de­clar­ing their heavy­weight con­tender the champ in a toe-to-toe bout with Am­gen’s oral block­buster Ote­zla, a must-win over a Cel­gene drug that Bris­tol My­ers agreed to di­vest in or­der to com­plete the Cel­gene buy­out.

Still miss­ing from the first turn of Phase III cards are the ac­tu­al hard da­ta gleaned from the study, some­thing that would au­to­mat­i­cal­ly be lined up against ri­vals. But Bris­tol My­ers ex­ecs are stak­ing their rep on the claim that they scored sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful piv­otal da­ta that demon­strate a win on the pri­ma­ry end­point on PASI 75 skin clear­ance for mod­er­ate to se­vere pa­tients, with a sec­ondary win on su­prema­cy over Ote­zla.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER